SSc in 2011: From mechanisms to medicines.
Findings from ongoing studies of imatinib in systemic sclerosis (SSc) were eagerly awaited in 2011, but results from these clinical trials have so far been disappointing. However, progress in the understanding of the mechanisms that underlie SSc pathogenesis could provide clues to novel targets for 2012 and beyond.
Université Paris Descartes, Faculté de Médecine, Service de Médecine Interne, Hôpital Cochin, 27 rue du Faubourg Saint Jacques, 75014 Paris, France. luc.mouthon@cch.aphp.fr
Luc
L
Mouthon
D001549:Benzamides; D001777:Blood Coagulation / Q000187:drug effects; D002986:Clinical Trials as Topic; D005355:Fibrosis / Q000150:complications* / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D000068877:Imatinib Mesylate; D058990:Molecular Targeted Therapy; D010879:Piperazines / Q000627:therapeutic use*; D015539:Platelet Activation / Q000187:drug effects; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D012595:Scleroderma, Systemic / Q000188:drug therapy* / Q000209:etiology* / Q000503:physiopathology; D016896:Treatment Outcome
D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate